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Summary: Lipoprotein(a) is a cholesterol-rich plasma lipoprotein consisting of LDL and apolipoprotein(a).
Apolipoprotein(a) shows structural similarity with plasminogen and thus may interfere with thrombogenesis.
Lipoprotein(a) has been shown to be a strong independent risk factor for coronary heart disease.
So far no drug or diet is known to have prominent effects on the serum levels of lipoprotein(a).
In the present study we found a highly significant decrease (in the order of 26%) of lipoprotein(a) in 28
women treated for 6 months with Tibolone, compared with an age-matched healthy control group.
Tibolone is a synthetic steroid with gestagenic and weak androgenic and oestrogenic properties, which shows
no stimulation of the endometrium. Tibolone also produced a decrease in HDL-cholesterol of 23% (p < 0.001),
a decrease in apolipoprotein A-I of 14% (p < 0.001) and an increase in apolipoprotein B of 17% (p < 0.001),
whereas the control group showed no significant changes in these quantities.
Tibolone in a daily dose of 2.5 mg is at present the only complete postmenopausal hormone replacement
therapy that shows a significant inhibiting influence on serum levels of lipoprotein(a). Its effect on lipoprotein(a)
might counterbalance, at least to some extent, the theoretical adverse effect on the other lipoprotein risk
factors.
Introduction ^
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Lipoprotein(a) is a cholesterol-rich plasma lipoprotein wide range between individuals but they are remark-
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 4 - .,,v y
 menopausal hormone replacement therapy with oes-
Lipoprotein(a) has been shown to be a genetically trogen has been shown to reduce low density lipopro-
determined independent risk factor for coronary heart tein and increase high density lipoprotein levels, with
disease (1, 4) and stroke (5) and its metabolism is a 40—50% decrease in the risk of cardiovascular
independent of that of low density lipoprotein. death (7). Little is known, however, about the effects
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of hormone replacement therapy on lipoprotein(a).
We therefore looked at changes in plasma lipoproteins
(low density lipoprotein-cholesterol, total high density
lipoprotein-cholesterol and subfractions, apolipopro-
tein A-I, apolipoprotein A-II, apolipoprotein B) and
lipoprotein(a) in a group of 28 post menopausal
women treated for 6 months with Tibolone (Livial®;
Organon International) and in a control group of
untreated volunteers. Tibolone is a synthetic steroid,
(7a,17a)-17-hydroxy-7-methyl-19-nor-pregn-5(10)-en-
20-yn-3-one, structurally related to the progestogens,
norethynodrel and norethisterone (fig. 1). It shows
Fig. 1. Chemical structure of Tibolone [Org OD 14: (7α,17α)-
17-hydroxy-7-methyl-l 9-nor-pregn-5(l 0)-en-20-yn-3-
one].
weak progestogenic, oestrogenic and androgenic ac-
tions in animal tests (8). Tibolone has been shown to
be effective in the relief of climacteric symptoms
(9 — 11) and in preventing post menopausal bone loss
(12). Tibolone is also effective in the treatment of
established postmenopausal osteoporosis (13). A fur-
ther advantage of Tibolone is the absence of endo-
metrial stimulation (14, 15). Thus, in non-hysterec-
tomized women no withdrawal bleeding occurs, an
otherwise leading cause for discontinuation of hor-
mone replacement therapy.
Patients and Methods
Patients
In 28 apparently healthy, early post menopausal women, serum
lipids, lipoprotein(a), low density lipoprotein- and high density
lipoprotein-cholesterol, and the apolipoproteins A-I, A-II and
Β were measured before and after 6 months of hormone sub-
stitution with Tibolone 2.5 mg daily. The results were compared
with a control group of 28 age-matched postmenopausal vol-
unteers not wishing to receive hormonal substitution therapy.
All women participating in the study were recruited among
patients consulting our endocrinological outpatient consulta-
tion for climacteric symptoms. None of the women had taken
oestrogen gestagen medication during at least 2 months prior
to the first examination, and none took lipid-lowering or any
other type of drug. They were advised not to change their diet
and smoking habits.
The major characteristics of the study population are given in
table 1. The two groups did not differ statistically. Menopause
was ascertained by serum follitropin values above 30 U/l.
All patients gave their informed consent to participation in the
study. The study protocol was approved by the ethical com-
mittee of the women's hospital of the University of Berne.
Tab. 1. Characteristics of study population. Data are presented
as mean ± SEM. Body-Mass-Index: weight in kg/
(height in cm)2 χ 10000.
There was no significant difference between the two
groups (Student's t test: p >.Q.05).
Controls Tibolone
Number of patients
Age (a)
Duration of menopause (a)
Weight (kg)
Height (cm)
Body-Mass-Index
Systolic blood pressure
(mmHg)
Diastolic blood pressure
(mmHg)
Hysterectomized
Bilateral ovarectomized
Smoker
Previous hormonal
replacement therapy
28
51.9 + 0.6
3.1 + 0.4
64.1 + 1.7
164.3 + 1.1
23.8 + 0.6
124.5 ± 3.2
78.0 ± 1.8
9
2
5
7
28
52.9 ± 0.7
3.5 ± 0.4
68.8 + 2.1
163.2 + 1.1
24.8 ± 0.6
126.1 ± 3.5
79.3 ± 1.8
11
1
5
9
Methods
Fasting blood samples were obtained from all subjects before
enrolment in the study and after 6 months. All sera were stored
at —20 °C until analysed. Total cholesterol and triacylglycerols
were measured by enzymatic methods (Boehringer Mannheim),
high density lipoprotein-cholesterol was determined after pre-
cipitation with phosphotungstate Mg?+ (Boehringer Mann-
heim), and low density lipoprotein-cholesterol was measured
after precipitation with an amphiphilic polymer (Bio Merieux,
Lyon) in the washed and re-dissolved precipitate. The high
density Hpoprotein2/high density Iipoprotein3 (HDL2/HDL3)-
ratio was measured by precipitation with polyethylene glycol
according to Kostner (16). Apolipoproteins A-I, A-II and B
were measured by immunonephelometry on a Behring Nephe-
lometer Analyser (Behririgwerke Marburg). The between-run
coefficient of variation for apolipoprotein-A-I was 4.6% at 1.7
g/1 and the within-run coefficient of variation was 1.8%. The
between-run coefficient of variation for apolipoprotein B was
3.3% at 1.22 g/1 and the within-run coefficient of variation was
1.9%. Apolipoprotein values were standardised with reference
material from Behring-Werke which is proposed as the WHO
standard.
Lipoprotein(a) was measured by immunoradiometric assay
(Pharmacia Uppsala). This method was shown not to be af-
fected by storage of samples in the frozen state. The between-
run coefficient of variation for lipoprotein(a) was 9.7% at 93
mg/1.
Statistical analysis
The comparison of initial values, treatment differences within
groups after 6 months and comparison of treatment changes
between groups were statistically analysed with Student's test.
For lipoprotein(a), which is known for its skewed distribution,
logarithmic transformation was performed before testing. Test-
ing was performed two-sided. All p-values below 0.05 were
considered to be significant.
JResults
Initial lipid and lipoprotein values did not differ be-
tween the two groups of volunteers (tab. 2). Lipopro-
tein(a) concentrations showed the typical skewed var-
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iation among individuals. At the start of the study, 8
of the 28 women in the control group and 4 of the
28 women in the treated group had lipoprotein(a)
values above the norm of 300 mg/1, this difference
was statistically not significant (jFXy/ier's exact test).
After 6 months of treatment with Tibolone, significant
changes were found in the values for high density
lipoprotein-cholesterol, the high density Iipoprotein2/
high density Iipoprotein3-ratio, apolipoprotein A-I
and apolipoprotein B, whereas no significant altera-
tions occurred in total cholesterol, triacylglycerols,
low density lipoprotein-cholesterol, very low density
lipoprotein-cholesterol and apolipoprotein A-II. High
density lipoprotein-cholesterol and apolipoprotein
A-I concentrations significantly decreased after Ti-
bolone treatment, whereas apolipoprotein B showed
a statistically significant increase (tab. 2). Within the
non-substituted group only the high density
Iipoprotein2/high density Iipoprotein3 ratio showed a
significant decrease after 6 months. In contrast to
apolipoprotein B, lipoprotein(a) showed a decrease of
26.1% in the treated group, while within the control
group an insignificant change of only 1.7% was ob-
served (tab. 2). When compared between the two
groups, the decrease of lipoprotein(a) after 6 months
under Tibolone treatment is highly significant
(p < 0.0002).
Twenty-four of the 28 lipoprotein(a) values showed a
decrease after treatment with Tibolone, the largest
decreases occurring in the 7 patients with the highest
pre-treatment values.
The mean change of lipoprotein(a) as a percentage of
the initial value in the 7 patients with highest initial
values (upper quartile) was 0.7% in the controls and
—42.9% in the treated group, this difference between
the two groups being highly significant (p < 0.004).
The individual changes in lipoprotein(a) levels are
illustrated in figure 2.
1200
Initial 6 months
Controls
Initial 6 month»
Tibolone
Fig. 2. Individual changes of serum levels of Upoprotein(a)
during 6 months in control and treatment groups.
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Discussion
It is well established that oestrogens and progestins
have different effects on lipoproteins. Oestrogens are
associated with a decrease in the atherogenic low
density lipoprotein fraction and with an increase in
the concentration of high density lipoprotein, shown
to be negatively associated with coronary heart dis-
ease. Tibolone, which was used in the present study,
is a synthetic steroid with oestrogenic, progestogenic
and weak androgenic activity. We confirmed an al-
ready known significant decrease in high density lipo-
protein-cholesterol (17) and its major apolipoprotein
A-I of 22.9% and 14.4%, respectively, in the treat-
ment group, probably due to the progestagenic and
androgenic properties of Tibolone. Concomitant with
the decrease in high density lipoprotein, there was
also a significant increase of the high density
Iipoprotein2/high density Iipoprotein3 (HDL2/HDL3)
ratio in the order of 17.9%, indicating that high
density Iipoprotein3 is decreased to a greater extent
than high density Iipoprotein2. The high density
Iipoprotein2 subfraction is regarded as the antiathero-
genic fraction of high density lipoprotein-cholesterol
(18). Furthermore, Klosterboer et al. demonstrated
that after treatment for 3 years, high density lipopro-
tein-cholesterol returned to pretreatment concentra-
tions (17). However, in view of the important decrease
of total high density lipoprotein, an increase of the
coronary risk has to be postulated.
On the other hand, recent data from experiments in
Cynomolgus monkeys showed that the extent of cor-
onary atherosclerosis was lessened by oestrogen ges-
tagen combination, despite the fact that serum con-
centrations of high density lipoprotein-cholesterol
were lowered (19).
In our treatment group no significant alteration was
observed for total cholesterol, triacylclycerols and low
density lipoprotein-cholesterol, while apolipoprotein
B showed a highly significant increase of 17.1%.
Elevated serum concentrations of apolipoprotein B
are significantly correlated with a higher risk for car-
diovascular disease in women (20). In both groups we
found no significant influence on triacylglycerol serum
concentrations, but there was a slight decrease of 4%
(Tibolone) and 6% (controls), compared with the
initial values. These results are not in accord with
earlier findings (17, 21) of a significant decrease (20%)
of triacylglycerol after Tibolone treatment. Elevated
concentrations of triacylglycerols are considered to be
associated with a higher risk for cardiovascular dis-
ease (22, 23).
The main focus of our study, however, was the re-
sponse of lipoprotein(a), (an independent risk factor
for coronary heart disease) to Tibolone treatment. It
is difficult to influence the lefvel of lipoprotein(a).
Conventional hormone replacement therapy with oral
oestrogens only marginally decreased serum concen-
trations of lipoprotein(a), probably due to a minor
influence on its hepatic synthesis (24). A decrease of
lipoprotein(a) in the order of 50%, due to combined
postmenopausal hormone replacement therapy with
1.25 mg conjugated oestrogens daily plus 10mg me-
droxyprogesterone acetate for 10 days a month as
described by Soma et al. (25) in 10 patients treated
for one year, was not confirmed by the data of Meus-
ing et al. (26). Further indications for an influence of
sex steroids on lipoprotein(a) levels are provided by
the results of Kühl et al. (27) who found a transitory
decrease of lipoprotein(a) in 19 premenopausal
women taking an oral contraceptive containing ethi-
nyloestradiol and desogestrel. Lipoprotein(a) de-
creased during the 3rd month and reached initial
values after 6 months. Two other publications deal
with the influence of oestradiol therapy on lipopro-
tein(a) in men treated for prostatic cancer. Lipopro-
tein(a) decreased to 50% after 6 months in 15 men
treated with oral ethinyloestradiol 150 g daily (28),
whereas the case report of a 67 year old man with
familial hypercholesterolaemia treated with 200 mg
diethylstilboestrol per day showed a decrease of lipo-
protein(a) of more than 80% after 4 weeks of treat-
ment (29).
Conventional lipid lowering drugs also have little
effect on this lipoprotein. The same holds true for
diet (30, 31). So far, decreases of lipoprotein(a) have
been obtained only with niacin and combination of
niacin and neomycin (32, 33), and by low density
lipoprotein apheresis (34).
Statistical analysis of plasma lipoprotein(a) levels is
difficult because of their extremely skewed distribu-
tion in the white race. In a non-selected population,
values above a cut-off-point of 300 mg/1, which are
thought to be associated with increased risk for cor-
onary heart disease, are observed in about 20% of
healthy volunteers (W. Riesen: MONICA-Switzer-
land, unpublished data). In our study group of 56
post menopausal women, lipoprotein(a) concentra-
tions above 300 mg/1 were observed in 21%.
In the group of 28 women treated with Tibolone there
was a highly significant decrease in» the concentrations
of lipoprotein(a). The mean decrease was 26.1%,
while in the untreated group a mean increase of 1.7%
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was observed. Compared with lipid lowering drug
treatment, where effects in the order of a 30% de-
crease are only seen with very potent lipid regulating
agents, the change of lipoprotein(a) with Tibolone
treatment is certainly remarkable. These findings are
consistent with the results of a pilot study by Parish
et al. (35) who demonstrated a significant decrease of
the median serum lipoprotein(a) values of 47% in 9
women treated with 10 mg norethisterone daily for 2
months. Tibolone shows a close structural similarity
to norethisterone. These data are compatible with an
unexpected constellation of a theoretically unfavour-
able fall of high density lipoprotein and a favourable
change of lipoprotein(a) values.
In conclusion, Tibolone is so far the only complete
post menopausal hormone replacement therapy that
shows a significant decrease of serum concentration
of lipoprotein(a) after an oral intake of 2.5 mg daily.
Its effort on lipoprotein(a) concentrations, however,
might counterbalance, at least to some extent, the
adverse effect of Tibolone on other lipoprotein risk
factors such as the important decrease of high density
lipoprotein-cholesterol and the significant increase in
apolipoprotein B. The clinical long-term effect of Ti-
bolone on the risk of coronary heart disease, known
to be elevated in unsubstituted post menopausal
women, has to be evaluated in prospective long term
studies.
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